OpenAI Loses Another AI Scientist to Booming Drug Discovery Gold Rush as Researcher Eyes $2 Billion Valuation

The artificial intelligence industry's brain drain into healthcare continues as Miles Wang, an OpenAI researcher specializing in biological discovery, prepares to launch an AI drug discovery startup that could debut with a $2 billion valuation before developing a single therapeutic.

According to reports from TechCrunch, Wang is in discussions to raise approximately $200 million in funding led by Lightspeed Venture Partners, with several fellow OpenAI researchers expected to join the venture. While Wang has disputed the reported valuation figures without providing corrections, the pharmaceutical and investment communities are closely watching what could become one of the year's most significant healthcare AI launches.

The Strategic Pivot to Drug Repurposing

Wang's startup reportedly plans to focus on identifying new uses for FDA-approved drugs and previously failed clinical trial candidates—a pragmatic application of AI that distinguishes it from competitors pursuing de novo drug discovery.

Drug repurposing dramatically shortens the traditional 10-15 year development timeline because existing safety data eliminates years of preclinical and early-phase clinical testing. For a startup seeking faster paths to revenue and clinical impact, this strategy could prove far more commercially viable than designing entirely new molecular entities.

Wang, a Harvard computer science dropout who joined OpenAI in 2024, co-authored research on AI-automated scientific discovery during his tenure. His work positioned him at the intersection of foundation models and biological applications—expertise now being redirected toward a focused commercial venture.

A Crowded and Well-Funded Field

Wang's startup enters an increasingly competitive landscape where AI drug discovery companies are commanding substantial valuations. This week, Chai Discovery announced a $400 million funding round at a $3.8 billion valuation. The company, which develops AI models for predicting molecular interactions, was co-founded by Josh Meier—also a former OpenAI researcher.

Meanwhile, Isomorphic Labs, the Google DeepMind spinout, raised a $2.1 billion Series B in May 2025, cementing its position as one of the sector's most valuable players. The pattern is clear: specialized AI applications in drug discovery are attracting massive capital commitments despite limited clinical validation to date.

This talent migration from general-purpose AI labs to healthcare-specific ventures signals investor confidence that foundation models have matured sufficiently for vertical applications. It also suggests that immediate commercial opportunities lie in applying existing models to high-value problems like pharmaceutical development rather than improving base AI capabilities.

Implications for Healthcare Stakeholders

For healthcare providers and health systems, the proliferation of AI drug repurposing platforms could accelerate access to treatment options for rare diseases and off-label applications with established safety profiles, reducing clinical uncertainty compared to entirely novel compounds.

Pharmaceutical companies and clinical data providers may find growing partnership opportunities as these startups require access to proprietary datasets, electronic health records, and real-world evidence to train and validate their models effectively.

However, the sector's elevated valuations raise questions about whether these companies can deliver clinical and commercial outcomes that justify their billion-dollar price tags—particularly as they compete for similar datasets, talent, and pharmaceutical partnerships.

The coming months will reveal whether Wang's venture can translate AI capabilities into tangible therapeutic advances, or whether the drug discovery gold rush represents another cycle of inflated expectations in healthcare technology.

Sources:
1. OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B — TechCrunch